Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation
Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the pre...
Saved in:
Published in | European journal of clinical investigation Vol. 45; no. 10; pp. 1060 - 1068 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Blackwell Publishing Ltd
01.10.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation.
Design
One‐hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP‐mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting.
Results
The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45–13·37), P < 0·01] and lower death‐censored graft survival [107·90 (84·19–131·62) vs. 176·89 (166·47–187·32) months for CYP2J2*1/*1 grafts; log‐rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively).
Conclusions
Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation. |
---|---|
AbstractList | Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation.
One-hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP-mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting.
The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45-13·37), P < 0·01] and lower death-censored graft survival [107·90 (84·19-131·62) vs. 176·89 (166·47-187·32) months for CYP2J2*1/*1 grafts; log-rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively).
Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation. BACKGROUNDArachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re-oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation.DESIGNOne-hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP-mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting.RESULTSThe CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45-13·37), P < 0·01] and lower death-censored graft survival [107·90 (84·19-131·62) vs. 176·89 (166·47-187·32) months for CYP2J2*1/*1 grafts; log-rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively).CONCLUSIONSTaken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation. Background Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a protective role against damaging processes that may occur after re‐oxygenation of the graft. We aimed to investigate whether the presence of functional polymorphisms along these metabolic routes may play a role in the outcome of renal transplantation. Design One‐hundred and forty Caucasian renal transplant recipients and 137 donors were included. We determined the presence of seven common functional polymorphisms in the five genes governing the CYP‐mediated AA metabolic pathway (CYP2C8, CYP2C9, CYP2J2, CYP4A11 and CYP4F2). Associations with parameters and events related to graft function and survival were retrospectively investigated throughout the first year after grafting. Results The CYP2J2*7 allele of the donor was significantly associated with higher risk for delayed graft function [OR = 4·40 (1·45–13·37), P < 0·01] and lower death‐censored graft survival [107·90 (84·19–131·62) vs. 176·89 (166·47–187·32) months for CYP2J2*1/*1 grafts; log‐rank P = 0·015]. In addition, patients whose donors carried the CYP4A11 434S variant of the F434S polymorphism displayed impaired creatinine clearance, with statistically significant differences vs. 434FF subjects throughout the whole period of study (P < 0·05, P < 0·01, P < 0·001 and P < 0·05 for 1 week, 1 month, 5 months and 1 year after grafting, respectively). Conclusions Taken together, these results indicate that variability in the CYP450 genes involved in the synthesis of eicosanoids from AA may have a significant impact on graft function and survival in renal transplantation. |
Author | Alvarado, Raul García-Cerrada, Montserrat Doblaré, Emilio Gervasini, Guillermo Vergara, Esther Fernández-Cavada, Maria Jesús Barroso, Sergio Cubero, Juan José García-Pino, Guadalupe |
Author_xml | – sequence: 1 givenname: Guillermo surname: Gervasini fullname: Gervasini, Guillermo email: ggervasi@unex.es organization: Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain – sequence: 2 givenname: Montserrat surname: García-Cerrada fullname: García-Cerrada, Montserrat organization: Department of Medical and Surgical Therapeutics, Division of Pharmacology, Medical School, University of Extremadura, Badajoz, Spain – sequence: 3 givenname: Esther surname: Vergara fullname: Vergara, Esther organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 4 givenname: Guadalupe surname: García-Pino fullname: García-Pino, Guadalupe organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 5 givenname: Raul surname: Alvarado fullname: Alvarado, Raul organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 6 givenname: Maria Jesús surname: Fernández-Cavada fullname: Fernández-Cavada, Maria Jesús organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 7 givenname: Sergio surname: Barroso fullname: Barroso, Sergio organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 8 givenname: Emilio surname: Doblaré fullname: Doblaré, Emilio organization: Service of Nephrology, Infanta Cristina University Hospital, Badajoz, Spain – sequence: 9 givenname: Juan José surname: Cubero fullname: Cubero, Juan José organization: Service of Immunology, Infanta Cristina University Hospital, Badajoz, Spain |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26214067$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1vEzEQhi3UiqaFA38A-QiHbf2x648jhBJatVAkEOJkOfasYthdp7Yjmn9f07Q9VALL0kij5x3NPIdob4oTIPSKkmNa3wm4cExZR-QzNKNcdA3jgu2hGSG0bZiW7AAd5vyLEKIoZ8_RAROMtkTIGbJXcdiOMa1XIY8ZhwnPf141I_hgC3hsk3Wr4OMUHLYueJzipkDGtu_BFVxWgGvDxbHWHieY7IBLslNeD3YqtoQ4vUD7vR0yvLyvR-j7x9Nv80_NxZfF2fzdReNazmXjnGZaO9X2tPMgFNVeQ299S1z9Soul1EJQrrRnjkjpW6U7zhWwZasdB36E3uzmrlO83kAuZgzZwVAXgbjJhkoqWEcVUxV9fY9ulvVUs05htGlrHrRU4O0OcCnmnKB_RCgxf5WbqtzcKa_syRPWhd3lVUQY_pf4EwbY_nu0OZ2fPSSaXSLkAjePCZt-m7qt7MyPzwvzdcEuz_X7S_OB3wIbyaC_ |
CitedBy_id | crossref_primary_10_1002_jev2_12026 crossref_primary_10_1002_phar_1928 crossref_primary_10_1016_j_kint_2022_04_033 crossref_primary_10_3390_ijms222112029 crossref_primary_10_1038_s41598_021_83274_1 crossref_primary_10_1080_03007995_2017_1391757 crossref_primary_10_1681_ASN_2017030252 crossref_primary_10_1111_eci_12819 crossref_primary_10_1038_s41397_019_0128_7 crossref_primary_10_3390_jcm10173980 crossref_primary_10_1080_07853890_2019_1614656 crossref_primary_10_1371_journal_pone_0224129 crossref_primary_10_1016_j_mce_2015_10_009 |
Cites_doi | 10.1097/00008571-199402000-00005 10.1016/j.prostaglandins.2009.04.004 10.1161/01.HYP.0000182658.04299.15 10.1126/science.285.5431.1276 10.1161/01.RES.0000139436.89654.c8 10.1097/00007691-200412000-00004 10.1016/j.prostaglandins.2011.11.007 10.1073/pnas.91.15.7002 10.1016/j.bbrc.2004.12.116 10.1097/00008571-200110000-00006 10.1016/j.atherosclerosis.2006.11.001 10.1006/abbi.1996.0229 10.1177/1076029611436197 10.1161/01.STR.0000016332.37292.59 10.1016/S0006-2952(02)01354-0 10.1111/j.1432-2277.2008.00829.x 10.1007/s00228-012-1355-x 10.1006/abbi.1995.1438 10.1074/jbc.272.19.12551 10.1016/S0003-4975(03)00735-5 10.1097/01.hjh.0000244944.34546.8e 10.1097/FPC.0000000000000045 10.1124/jpet.110.167510 10.1152/physiolgenomics.00003.2007 10.1096/fj.10-171488 10.1124/jpet.109.159863 10.1152/ajprenal.00350.2004 10.1097/00008571-199608000-00007 10.1161/01.CIR.0000143832.91812.60 10.1096/fj.10-160119 10.1161/01.CIR.0000151309.82473.59 10.1124/mol.61.4.840 10.1111/j.1432-2277.2012.01446.x 10.1074/jbc.275.6.4118 10.1016/j.atherosclerosis.2009.06.009 10.1002/jcph.15 10.1097/FPC.0b013e32830e1e16 10.1016/j.transproceed.2008.03.137 10.1540/jsmr.41.175 10.1074/jbc.R100030200 |
ContentType | Journal Article |
Copyright | 2015 Stichting European Society for Clinical Investigation Journal Foundation 2015 Stichting European Society for Clinical Investigation Journal Foundation. |
Copyright_xml | – notice: 2015 Stichting European Society for Clinical Investigation Journal Foundation – notice: 2015 Stichting European Society for Clinical Investigation Journal Foundation. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1111/eci.12507 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2362 |
EndPage | 1068 |
ExternalDocumentID | 26214067 10_1111_eci_12507 ECI12507 ark_67375_WNG_QG2MJ9BM_D |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Comercio e Innovacion – fundername: Association for the Study and Prevention of Renal Diseases (ASEPER) – fundername: Junta de Extremadura funderid: GR10022 – fundername: Consejeria de Economia |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 29G 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABLJU ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO EAD EAP EAS EBB EBC EBD EBS EBX EJD EMB EMK EMOBN EPT ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TUS UB1 W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZGI ZXP ZZTAW ~IA ~WT AAHQN AAIPD AAMNL AANHP AAYCA ACRPL ACUHS ACYXJ ADNMO AFWVQ ALVPJ AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
ID | FETCH-LOGICAL-c4337-cc9299c84f15de6819d9efad40c40c896b79661389d2c077d4895338e2b49c3e3 |
IEDL.DBID | DR2 |
ISSN | 0014-2972 |
IngestDate | Thu Jul 10 19:55:10 EDT 2025 Wed Feb 19 01:57:46 EST 2025 Thu Apr 24 22:57:21 EDT 2025 Tue Jul 01 00:53:25 EDT 2025 Wed Jan 22 16:43:04 EST 2025 Wed Oct 30 09:52:21 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | graft survival Creatinine clearance CYP450 polymorphisms delayed graft function renal transplant |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2015 Stichting European Society for Clinical Investigation Journal Foundation. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4337-cc9299c84f15de6819d9efad40c40c896b79661389d2c077d4895338e2b49c3e3 |
Notes | Comercio e Innovacion Figure S1. Epoxygenase and hydroxylase pathways of arachidonic acid metabolismTable S1. Multivariate logistic regression model for the risk of delayed graft function in renal transplant recipients. Table S2. Creatinine clearance values at the four time-points considered stratified by donor and recipient genotype. Table S3. Serum creatinine concentrations (mg/dL) stratified by donor and recipient genotype at the four time-points considered. Junta de Extremadura - No. GR10022 ArticleID:ECI12507 istex:804031AFD3A13F26552581D3E8AD73DA4DE0766F Association for the Study and Prevention of Renal Diseases (ASEPER) Consejeria de Economia ark:/67375/WNG-QG2MJ9BM-D ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 26214067 |
PQID | 1716251828 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1716251828 pubmed_primary_26214067 crossref_primary_10_1111_eci_12507 crossref_citationtrail_10_1111_eci_12507 wiley_primary_10_1111_eci_12507_ECI12507 istex_primary_ark_67375_WNG_QG2MJ9BM_D |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | October 2015 |
PublicationDateYYYYMMDD | 2015-10-01 |
PublicationDate_xml | – month: 10 year: 2015 text: October 2015 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | European journal of clinical investigation |
PublicationTitleAlternate | Eur J Clin Invest |
PublicationYear | 2015 |
Publisher | Blackwell Publishing Ltd |
Publisher_xml | – name: Blackwell Publishing Ltd |
References | Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330:87-96. King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52. Fu Z, Ma Y, Xie X, Huang D, Yang H, Nakayama T et al. A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 2013;19:60-5. Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256-62. Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14. Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6. Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9. Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002;33:1677-84. Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276:36059-62. Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6. Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994;91:7002-6. Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013;69:385-93. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74-81. Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24:3770-81. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005;41:175-93. Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34. Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111:63-9. Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat 2009;89:43-51. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012;25:471-80. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42. Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg 2003;76:1623-30. Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607. Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D et al. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010;332:57-65. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600-8. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89. Dolegowska B, Blogowski W, Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report Transpl Int 2009;22:546-53. Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011;25:703-13. Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46:766-71. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275:4118-26. Hermann M, Hellermann JP, Quitzau K, Hoffmann MM, Gasser T, Meinertz T et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207:476-9. Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-94. Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995;322:76-86. Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503. Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012;98:75-85. Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24:1965-70. Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206. Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18:943-53. 2009; 89 2009; 22 2013; 69 2005; 111 1997; 272 2008; 18 2004; 26 2002; 33 1999; 285 2005; 41 2014; 24 2000; 275 2007; 30 2012; 98 2003; 76 2005; 46 2001; 276 2013; 19 2004; 110 2004; 95 2010; 24 2002; 64 2007; 195 2006; 24 2002; 61 2005; 289 2010; 334 2013; 53 2010; 332 2005; 327 1996; 330 1995; 322 2011; 25 2001; 11 2012; 25 1994; 91 2009; 207 2008; 40 1994; 4 1996; 6 e_1_2_9_30_1 e_1_2_9_31_1 e_1_2_9_11_1 e_1_2_9_34_1 e_1_2_9_10_1 e_1_2_9_35_1 e_1_2_9_13_1 e_1_2_9_32_1 e_1_2_9_12_1 e_1_2_9_33_1 e_1_2_9_15_1 e_1_2_9_38_1 e_1_2_9_14_1 e_1_2_9_39_1 e_1_2_9_17_1 e_1_2_9_36_1 e_1_2_9_16_1 e_1_2_9_37_1 e_1_2_9_19_1 e_1_2_9_18_1 e_1_2_9_20_1 e_1_2_9_40_1 Woillard JB (e_1_2_9_41_1) 2014; 24 e_1_2_9_22_1 e_1_2_9_21_1 e_1_2_9_24_1 e_1_2_9_23_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_26_1 e_1_2_9_25_1 e_1_2_9_28_1 e_1_2_9_27_1 e_1_2_9_29_1 |
References_xml | – reference: Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001;11:597-607. – reference: Sharma M, McCarthy ET, Reddy DS, Patel PK, Savin VJ, Medhora M et al. 8,9-Epoxyeicosatrienoic acid protects the glomerular filtration barrier. Prostaglandins Other Lipid Mediat 2009;89:43-51. – reference: Fava C, Ricci M, Melander O, Minuz P. Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex-specific relation? Prostaglandins Other Lipid Mediat 2012;98:75-85. – reference: Cheng J, Wu CC, Gotlinger KH, Zhang F, Falck JR, Narsimhaswamy D et al. 20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling. J Pharmacol Exp Ther 2010;332:57-65. – reference: Liu PY, Li YH, Chao TH, Wu HL, Lin LJ, Tsai LM et al. Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction. Atherosclerosis 2007;195:199-206. – reference: Dolegowska B, Blogowski W, Domanski L. Is it possible to predict the early post-transplant allograft function using 20-HETE measurements? A preliminary report Transpl Int 2009;22:546-53. – reference: Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012;25:471-80. – reference: Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002;64:1579-89. – reference: Alkayed NJ, Goyagi T, Joh HD, Klaus J, Harder DR, Traystman RJ et al. Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack. Stroke 2002;33:1677-84. – reference: Xiao B, Li X, Yan J, Yu X, Yang G, Xiao X et al. Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide. J Pharmacol Exp Ther 2010;334:784-94. – reference: Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42. – reference: Seubert J, Yang B, Bradbury JA, Graves J, Degraff LM, Gabel S et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 2004;95:506-14. – reference: Zeldin DC, DuBois RN, Falck JR, Capdevila JH. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch Biochem Biophys 1995;322:76-86. – reference: Woillard JB, Picard N, Thierry A, Touchard G, Marquet P. Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients. Pharmacogenet Genomics 2014;24:256-62. – reference: King LM, Ma J, Srettabunjong S, Graves J, Bradbury JA, Li L et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52. – reference: Gervasini G, Garcia M, Macias RM, Benitez J, Caravaca F, Cubero JJ. CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors. J Clin Pharmacol 2013;53:427-34. – reference: Fu Z, Ma Y, Xie X, Huang D, Yang H, Nakayama T et al. A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease. Clin Appl Thromb Hemost 2013;19:60-5. – reference: Wu S, Chen W, Murphy E, Gabel S, Tomer KB, Foley J et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9. – reference: Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res 2005;41:175-93. – reference: Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK. Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 2000;275:4118-26. – reference: Smith HE, Jones JP 3rd, Kalhorn TF, Farin FM, Stapleton PL, Davis CL et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008;18:943-53. – reference: Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD et al. Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 1996;330:87-96. – reference: Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9. – reference: Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y et al. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005;111:63-9. – reference: Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 2007;30:74-81. – reference: Yang Q, Zhang RZ, Yim AP, He GW. Effect of 11,12-epoxyeicosatrienoic acid as an additive to St. Thomas' cardioplegia and University of Wisconsin solutions on endothelium-derived hyperpolarizing factor-mediated function in coronary microarteries: influence of temperature and time. Ann Thorac Surg 2003;76:1623-30. – reference: Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9. – reference: Paller MS, Jacob HS. Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 1994;91:7002-6. – reference: Lundblad MS, Stark K, Eliasson E, Oliw E, Rane A. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes. Biochem Biophys Res Commun 2005;327:1052-7. – reference: Mayer B, Lieb W, Gotz A, Konig IR, Aherrahrou Z, Thiemig A et al. Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy. Hypertension 2005;46:766-71. – reference: Zeldin DC. Epoxygenase pathways of arachidonic acid metabolism. J Biol Chem 2001;276:36059-62. – reference: Hermann M, Hellermann JP, Quitzau K, Hoffmann MM, Gasser T, Meinertz T et al. CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease-the ENCORE Trials. Atherosclerosis 2009;207:476-9. – reference: Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G. ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. Eur J Clin Pharmacol 2013;69:385-93. – reference: Lee CR, Imig JD, Edin ML, Foley J, DeGraff LM, Bradbury JA et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J 2010;24:3770-81. – reference: Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004;26:600-8. – reference: Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 2005;289:F496-503. – reference: Deng Y, Edin ML, Theken KN, Schuck RN, Flake GP, Kannon MA et al. Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J 2011;25:703-13. – reference: Mayer B, Lieb W, Gotz A, Konig IR, Kauschen LF, Linsel-Nitschke P et al. Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction. J Hypertens 2006;24:1965-70. – reference: Lee SH, Lee J, Cha R, Park MH, Ha JW, Kim S et al. Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation. Transplant Proc 2008;40:1353-6. – reference: Spiecker M, Darius H, Hankeln T, Soufi M, Sattler AM, Schaefer JR et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6. – volume: 24 start-page: 3770 year: 2010 end-page: 81 article-title: Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in mice publication-title: FASEB J – volume: 11 start-page: 597 year: 2001 end-page: 607 article-title: Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid publication-title: Pharmacogenetics – volume: 64 start-page: 1579 year: 2002 end-page: 89 article-title: CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha‐hydroxylase activity in human liver microsomes publication-title: Biochem Pharmacol – volume: 330 start-page: 87 year: 1996 end-page: 96 article-title: Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway publication-title: Arch Biochem Biophys – volume: 275 start-page: 4118 year: 2000 end-page: 26 article-title: Formation of 20‐hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11 publication-title: J Biol Chem – volume: 41 start-page: 175 year: 2005 end-page: 93 article-title: Role of 20‐hydroxyeicosatetraenoic acid (20‐HETE) in vascular system publication-title: J Smooth Muscle Res – volume: 334 start-page: 784 year: 2010 end-page: 94 article-title: Overexpression of cytochrome P450 epoxygenases prevents development of hypertension in spontaneously hypertensive rats by enhancing atrial natriuretic peptide publication-title: J Pharmacol Exp Ther – volume: 207 start-page: 476 year: 2009 end-page: 9 article-title: CYP4A11 polymorphism correlates with coronary endothelial dysfunction in patients with coronary artery disease–the ENCORE Trials publication-title: Atherosclerosis – volume: 33 start-page: 1677 year: 2002 end-page: 84 article-title: Neuroprotection and P450 2C11 upregulation after experimental transient ischemic attack publication-title: Stroke – volume: 19 start-page: 60 year: 2013 end-page: 5 article-title: A novel polymorphism of the CYP4A11 gene is associated with coronary artery disease publication-title: Clin Appl Thromb Hemost – volume: 332 start-page: 57 year: 2010 end-page: 65 article-title: 20‐hydroxy‐5,8,11,14‐eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase‐dependent endothelial nitric‐oxide synthase uncoupling publication-title: J Pharmacol Exp Ther – volume: 91 start-page: 7002 year: 1994 end-page: 6 article-title: Cytochrome P‐450 mediates tissue‐damaging hydroxyl radical formation during reoxygenation of the kidney publication-title: Proc Natl Acad Sci USA – volume: 18 start-page: 943 year: 2008 end-page: 53 article-title: Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor‐induced chronic kidney disease publication-title: Pharmacogenet Genomics – volume: 25 start-page: 471 year: 2012 end-page: 80 article-title: Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation publication-title: Transpl Int – volume: 195 start-page: 199 year: 2007 end-page: 206 article-title: Synergistic effect of cytochrome P450 epoxygenase CYP2J2*7 polymorphism with smoking on the onset of premature myocardial infarction publication-title: Atherosclerosis – volume: 289 start-page: F496 year: 2005 end-page: 503 article-title: Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases publication-title: Am J Physiol Renal Physiol – volume: 30 start-page: 74 year: 2007 end-page: 81 article-title: Functional polymorphism in human CYP4F2 decreases 20‐HETE production publication-title: Physiol Genomics – volume: 272 start-page: 12551 year: 1997 end-page: 9 article-title: Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes publication-title: J Biol Chem – volume: 285 start-page: 1276 year: 1999 end-page: 9 article-title: Anti‐inflammatory properties of cytochrome P450 epoxygenase‐derived eicosanoids publication-title: Science – volume: 89 start-page: 43 year: 2009 end-page: 51 article-title: 8,9‐Epoxyeicosatrienoic acid protects the glomerular filtration barrier publication-title: Prostaglandins Other Lipid Mediat – volume: 111 start-page: 63 year: 2005 end-page: 9 article-title: Functional variant of CYP4A11 20‐hydroxyeicosatetraenoic acid synthase is associated with essential hypertension publication-title: Circulation – volume: 53 start-page: 427 year: 2013 end-page: 34 article-title: CYP2C8*3 polymorphism and donor age are associated with allograft dysfunction in kidney transplant recipients treated with calcineurin inhibitors publication-title: J Clin Pharmacol – volume: 95 start-page: 506 year: 2004 end-page: 14 article-title: Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP‐sensitive K+ channels and p42/p44 MAPK pathway publication-title: Circ Res – volume: 76 start-page: 1623 year: 2003 end-page: 30 article-title: Effect of 11,12‐epoxyeicosatrienoic acid as an additive to St. Thomas’ cardioplegia and University of Wisconsin solutions on endothelium‐derived hyperpolarizing factor‐mediated function in coronary microarteries: influence of temperature and time publication-title: Ann Thorac Surg – volume: 4 start-page: 39 year: 1994 end-page: 42 article-title: Impaired (S)‐warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 publication-title: Pharmacogenetics – volume: 322 start-page: 76 year: 1995 end-page: 86 article-title: Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform publication-title: Arch Biochem Biophys – volume: 25 start-page: 703 year: 2011 end-page: 13 article-title: Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice publication-title: FASEB J – volume: 24 start-page: 1965 year: 2006 end-page: 70 article-title: Association of a functional polymorphism in the CYP4A11 gene with systolic blood pressure in survivors of myocardial infarction publication-title: J Hypertens – volume: 6 start-page: 341 year: 1996 end-page: 9 article-title: The role of the CYP2C9‐Leu359 allelic variant in the tolbutamide polymorphism publication-title: Pharmacogenetics – volume: 40 start-page: 1353 year: 2008 end-page: 6 article-title: Genetic variations in soluble epoxide hydrolase and graft function in kidney transplantation publication-title: Transplant Proc – volume: 22 start-page: 546 year: 2009 end-page: 53 article-title: Is it possible to predict the early post‐transplant allograft function using 20‐HETE measurements? A preliminary report publication-title: Transpl Int – volume: 24 start-page: 256 year: 2014 end-page: 62 article-title: Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients publication-title: Pharmacogenet Genomics – volume: 276 start-page: 36059 year: 2001 end-page: 62 article-title: Epoxygenase pathways of arachidonic acid metabolism publication-title: J Biol Chem – volume: 98 start-page: 75 year: 2012 end-page: 85 article-title: Hypertension, cardiovascular risk and polymorphisms in genes controlling the cytochrome P450 pathway of arachidonic acid: a sex‐specific relation? publication-title: Prostaglandins Other Lipid Mediat – volume: 46 start-page: 766 year: 2005 end-page: 71 article-title: Association of the T8590C polymorphism of CYP4A11 with hypertension in the MONICA Augsburg echocardiographic substudy publication-title: Hypertension – volume: 327 start-page: 1052 year: 2005 end-page: 7 article-title: Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes publication-title: Biochem Biophys Res Commun – volume: 61 start-page: 840 year: 2002 end-page: 52 article-title: Cloning of CYP2J2 gene and identification of functional polymorphisms publication-title: Mol Pharmacol – volume: 69 start-page: 385 year: 2013 end-page: 93 article-title: ABCB1 polymorphisms are associated with cyclosporine‐induced nephrotoxicity and gingival hyperplasia in renal transplant recipients publication-title: Eur J Clin Pharmacol – volume: 110 start-page: 2132 year: 2004 end-page: 6 article-title: Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2 publication-title: Circulation – volume: 26 start-page: 600 year: 2004 end-page: 8 article-title: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5 publication-title: Ther Drug Monit – ident: e_1_2_9_14_1 doi: 10.1097/00008571-199402000-00005 – ident: e_1_2_9_18_1 doi: 10.1016/j.prostaglandins.2009.04.004 – ident: e_1_2_9_37_1 doi: 10.1161/01.HYP.0000182658.04299.15 – ident: e_1_2_9_3_1 doi: 10.1126/science.285.5431.1276 – ident: e_1_2_9_30_1 doi: 10.1161/01.RES.0000139436.89654.c8 – ident: e_1_2_9_40_1 doi: 10.1097/00007691-200412000-00004 – ident: e_1_2_9_25_1 doi: 10.1016/j.prostaglandins.2011.11.007 – ident: e_1_2_9_19_1 doi: 10.1073/pnas.91.15.7002 – ident: e_1_2_9_24_1 doi: 10.1016/j.bbrc.2004.12.116 – ident: e_1_2_9_10_1 doi: 10.1097/00008571-200110000-00006 – ident: e_1_2_9_27_1 doi: 10.1016/j.atherosclerosis.2006.11.001 – ident: e_1_2_9_8_1 doi: 10.1006/abbi.1996.0229 – ident: e_1_2_9_26_1 doi: 10.1177/1076029611436197 – ident: e_1_2_9_5_1 doi: 10.1161/01.STR.0000016332.37292.59 – ident: e_1_2_9_12_1 doi: 10.1016/S0006-2952(02)01354-0 – ident: e_1_2_9_20_1 doi: 10.1111/j.1432-2277.2008.00829.x – ident: e_1_2_9_21_1 doi: 10.1007/s00228-012-1355-x – ident: e_1_2_9_33_1 doi: 10.1006/abbi.1995.1438 – ident: e_1_2_9_6_1 doi: 10.1074/jbc.272.19.12551 – ident: e_1_2_9_31_1 doi: 10.1016/S0003-4975(03)00735-5 – ident: e_1_2_9_38_1 doi: 10.1097/01.hjh.0000244944.34546.8e – volume: 24 start-page: 256 year: 2014 ident: e_1_2_9_41_1 article-title: Associations between polymorphisms in target, metabolism, or transport proteins of mycophenolate sodium and therapeutic or adverse effects in kidney transplant patients publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000045 – ident: e_1_2_9_29_1 doi: 10.1124/jpet.110.167510 – ident: e_1_2_9_15_1 doi: 10.1152/physiolgenomics.00003.2007 – ident: e_1_2_9_32_1 doi: 10.1096/fj.10-171488 – ident: e_1_2_9_35_1 doi: 10.1124/jpet.109.159863 – ident: e_1_2_9_2_1 doi: 10.1152/ajprenal.00350.2004 – ident: e_1_2_9_13_1 doi: 10.1097/00008571-199608000-00007 – ident: e_1_2_9_28_1 doi: 10.1161/01.CIR.0000143832.91812.60 – ident: e_1_2_9_17_1 doi: 10.1096/fj.10-160119 – ident: e_1_2_9_16_1 doi: 10.1161/01.CIR.0000151309.82473.59 – ident: e_1_2_9_11_1 doi: 10.1124/mol.61.4.840 – ident: e_1_2_9_23_1 doi: 10.1111/j.1432-2277.2012.01446.x – ident: e_1_2_9_9_1 doi: 10.1074/jbc.275.6.4118 – ident: e_1_2_9_36_1 doi: 10.1016/j.atherosclerosis.2009.06.009 – ident: e_1_2_9_22_1 doi: 10.1002/jcph.15 – ident: e_1_2_9_34_1 doi: 10.1097/FPC.0b013e32830e1e16 – ident: e_1_2_9_39_1 doi: 10.1016/j.transproceed.2008.03.137 – ident: e_1_2_9_4_1 doi: 10.1540/jsmr.41.175 – ident: e_1_2_9_7_1 doi: 10.1074/jbc.R100030200 |
SSID | ssj0008132 |
Score | 2.1988113 |
Snippet | Background
Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known... Arachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to play a... BACKGROUNDArachidonic acid (AA) is metabolized by cytochrome P450 (CYP) enzymes to vasoactive metabolites (mainly epoxyeicosatrienoic acids) which are known to... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1060 |
SubjectTerms | Adult Allografts - physiology Arachidonic Acid - genetics Arachidonic Acid - metabolism Creatinine clearance CYP450 Cytochrome P-450 Enzyme System - genetics Cytochrome P-450 Enzyme System - metabolism delayed graft function Female Genotype Graft Survival Homozygote Humans Kidney Diseases - genetics Kidney Diseases - metabolism Kidney Diseases - surgery Kidney Transplantation Male Middle Aged Polymorphism, Genetic - genetics polymorphisms renal transplant Retrospective Studies |
Title | Polymorphisms in CYP-mediated arachidonic acid routes affect the outcome of renal transplantation |
URI | https://api.istex.fr/ark:/67375/WNG-QG2MJ9BM-D/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Feci.12507 https://www.ncbi.nlm.nih.gov/pubmed/26214067 https://www.proquest.com/docview/1716251828 |
Volume | 45 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9RAFD6UFsQXtfXSVVtGEelLls1kchl86m67rYUtVSxWEIa5BUO3iewFtE_9Cf5Gf0nPTC5aqSBCICGcZCYzc3K-M3PONwCv0ETpOA1tEOY5OiixooEyXAYmYiaUCm2cnxqYHCeHp-zoLD5bgTdtLkzND9FNuDnN8P9rp-BSzX9TcquLPlpnn0nuYrUcIHr_izoqC6OaKTxkAeUpbViFXBRP9-QNW7TmmvXbbUDzJm71hmd8Hz63Va7jTc77y4Xq68s_2Bz_85sewL0GkJLdegStw4otN-DOpFlyfwj6pJp-v6iwO4r5xZwUJRl9Ovl59cOnnCBcJY7w-UthHMUukbowZFYtEb8S6SNFCAJMgjewJnjOycy60haeUn0q67yn8hGcjvc_jA6DZmeGQLMoSgOtEVVxnbE8jI1NEFUYbnNp2EDjkfFEpehGuTVQQ_UgTQ3LXBhrZqliXEc2egyrZVXaTSBUqUQluaWpZvhuR0AfxhlPOU10lslBD3baPhK6oS13u2dMReu-YKMJ32g9eNmJfq25Om4Teu07upOQs3MX3JbG4uPxgXh3QCdHfDgRez140Y4EgSrn1lFkaavlXDiGIYSF6Kv24Ek9RLq30YSiy5pgMTu-o_9eEbE_eusvnv676DO4i4AtroMJn8PqYra0WwiKFmob1naHe8PxtteCawQ8B7k |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9QwEB5VrQS8cB_LaRBCfclq4ziHJV5gabstzaqgVpQHZPmKiLpN0B4S8MRP4DfySxg7BxQVCSFFShRNYsf2ZL6xZz4DPEUTpeM0tEFYFOigxIoGynAZmIiZUCq0cX5qIJ8mkyO2dxwfr8HzLhem4YfoJ9ycZvj_tVNwNyH9m5ZbXQ7RPLtU8g23o7d3qN7-Io_KwqjhCg9ZQHlKW14hF8fTP3rGGm24hv18HtQ8i1y96dm-Ah-6SjcRJyfD1VIN9dc_-Bz_96uuwuUWk5IXzSC6Bmu2ug4X8nbV_Qbog3r25bTGHikXpwtSVmT8_uDHt-8-6wQRK3Gczx9L41h2idSlIfN6hRCWSB8sQhBjEryBVcFzQebWlbb0rOoz2aQ-VTfhaHvrcDwJ2s0ZAs2iKA20RmDFdcaKMDY2QWBhuC2kYSONR8YTlaIn5ZZBDdWjNDUsc5GsmaWKcR3Z6BasV3Vl7wChSiUqKSxNNcN3Ow76MM54ymmis0yOBrDZdZLQLXO520BjJjoPBhtN-EYbwJNe9FND13Ge0DPf072EnJ-4-LY0Fu-mO-LNDs33-MtcvBrA424oCNQ6t5QiK1uvFsKRDCEyRHd1ALebMdK_jSYUvdYEi9n0Pf33ioit8a6_uPvvoo_g4uQw3xf7u9PX9-AS4re4iS28D-vL-co-QIy0VA-9KvwEJbsKYg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7LLiy-eL-M1ygi-9JhmqZpgk86s7MXnWEUF1cQQm7FsrPtMhdQn_wJ_kZ_iSfpRVdWEKHQUk6bNDmn5zvJyReEnoKLMmkWuyjOcwhQUk0ibYWKbEJtrDT4uDA0MJmy_SN6eJweb6Dn7VqYmh-iG3DzlhH-197Az2z-m5E7U_TBO_uV5FuUDbhX6dHbX9xRPE5qqvCYRkRkpKEV8mk83aPnnNGWb9fPFyHN88A1eJ7xFfSxrXOdcHLSX69033z9g87xPz_qKrrcIFL8olaha2jDldfR9qSZc7-BzKyafzmtoD-K5ekSFyUefpj9-PY9rDkBvIo94_OnwnqOXaxMYfGiWgOAxSqkimBAmBhuQE3gnOOF86WtAqf6XNULn8qb6Gi8-264HzVbM0SGJkkWGQOwShhO8zi1jgGssMLlytKBgYMLpjOIo_wkqCVmkGWWcp_Hyh3RVJjEJbfQZlmV7g7CRGumWe5IZii82zPQxykXmSDMcK4GPbTT9pE0DW-53z5jLtv4BRpNhkbroSed6FlN1nGR0LPQ0Z2EWpz47LYsle-ne_LNHpkcipcTOeqhx60mSLA5P5GiSletl9JTDAEuhGC1h27XKtK9jTACMSuDYnZCR_-9InJ3eBAu7v676CO0PRuN5euD6at76BKAt7ROLLyPNleLtXsAAGmlHwZD-AkcUgka |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Polymorphisms+in+CYP%E2%80%90mediated+arachidonic+acid+routes+affect+the+outcome+of+renal+transplantation&rft.jtitle=European+journal+of+clinical+investigation&rft.au=Gervasini%2C+Guillermo&rft.au=Garc%C3%ADa%E2%80%90Cerrada%2C+Montserrat&rft.au=Vergara%2C+Esther&rft.au=Garc%C3%ADa%E2%80%90Pino%2C+Guadalupe&rft.date=2015-10-01&rft.issn=0014-2972&rft.eissn=1365-2362&rft.volume=45&rft.issue=10&rft.spage=1060&rft.epage=1068&rft_id=info:doi/10.1111%2Feci.12507&rft.externalDBID=10.1111%252Feci.12507&rft.externalDocID=ECI12507 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2972&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2972&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2972&client=summon |